Related Experiment Video
Updated: Feb 3, 2026

Generation and Expansion of Human Cardiomyocytes from Patient Peripheral Blood Mononuclear Cells
Published on: February 12, 2021
Fingolimod reduces circulating tight-junction protein levels and in vitro peripheral blood mononuclear cells
Pasquale Annunziata1, Chiara Cioni2, Gianni Masi2
1Department of Medicine, Surgery and Neurosciences, University of Siena, Siena, Italy. annunziata@unisi.it.
Abstract:
There are no data on the effects of fingolimod, an immunomodulatory drug used in treatment of multiple sclerosis (MS), on circulating tight-junction (TJ) protein levels as well as on peripheral blood mononuclear cells (PBMC) migration. Serum TJ protein [occludin (OCLN), claudin-5 (CLN-5) and zonula occludens-1 (ZO-1)] levels, sphingosine-1 phosphate 1 (S1P1) receptor expression on circulating leukocyte populations as well as in vitro PBMC migration were longitudinally assessed in 20 MS patients under 12-months fingolimod treatment and correlated with clinical and magnetic resonance imaging (MRI) parameters. After 12 months of treatment, a significant reduction of mean relapse rate as well as number of active lesions at MRI was found. TJ protein levels significantly decreased and were associated with reduction of S1P1 expression as well as of PBMC in vitro migratory activity. A significant correlation of CLN-5/OCLN ratio with new T2 MRI lesions and a significant inverse correlation of CLN-5/ZO-1 ratio with disability scores were found. These findings support possible in vivo effects of fingolimod on the blood-brain barrier (BBB) functional activity as well as on peripheral cell trafficking that could result in avoiding passage of circulating autoreactive cells into brain parenchyma. Circulating TJ protein levels and respective ratios could be further studied as a novel candidate biomarker of BBB functional status to be monitored in course of fingolimod as well as of other immunomodulatory treatments in MS.
Insights
Fingolimod treatment for multiple sclerosis (MS) reduced relapses and active lesions. It also decreased circulating tight-junction proteins, impacting cell migration and potentially the blood-brain barrier (BBB).
Area of Science:
- Neuroimmunology
- Cell Biology
- Biochemistry
Background:
- Multiple sclerosis (MS) is an autoimmune disease affecting the central nervous system.
- Fingolimod is an immunomodulatory drug used for MS treatment.
- The effects of fingolimod on circulating tight-junction (TJ) proteins and peripheral blood mononuclear cell (PBMC) migration are unknown.
Purpose of the Study:
- To investigate the impact of fingolimod on serum TJ protein levels (occludin, claudin-5, ZO-1) in MS patients.
- To assess changes in sphingosine-1 phosphate 1 (S1P1) receptor expression and in vitro PBMC migration.
- To correlate these changes with clinical and MRI parameters during 12 months of fingolimod treatment.
Main Methods:
- Longitudinal assessment of serum TJ proteins, S1P1 receptor expression on leukocytes, and in vitro PBMC migration in 20 MS patients.
- Correlation analysis with clinical data and MRI findings (relapse rate, active lesions, disability scores).
Main Results:
- Fingolimod treatment significantly reduced MS relapse rates and active MRI lesions after 12 months.
- Serum TJ protein levels, S1P1 receptor expression, and PBMC migratory activity significantly decreased.
- Specific TJ protein ratios (CLN-5/OCLN, CLN-5/ZO-1) correlated with MRI lesions and disability scores.
Conclusions:
- Fingolimod may exert in vivo effects on blood-brain barrier (BBB) function and peripheral cell trafficking in MS.
- These effects could prevent autoreactive cells from entering the brain.
- Circulating TJ proteins and their ratios may serve as novel biomarkers for BBB status during MS treatment.
Related Concept Videos
Tight Junctions
Multiple Allele Traits
Cell Migration
Cell Migration
Protein Buffers in Blood Plasma and Cells
Certain amino acids can exist in a zwitterion state at a...
Overview of Cell-Cell Junctions
Occluding or Tight...

